Pregnant woman resting in warm morning light, hand on her belly

MaiRa

Preeclampsia risk read from one blood draw in the first trimester, while there is still time to act

First-trimester cfRNA test, weeks 9 to 14Valencia, Spain

From one tube of blood to a risk you can act on

  1. Sample, wk 9 to 14
  2. cfRNA signature
  3. AI risk estimate
  4. Act before wk 16

Illustrative example, not patient data. Scroll to follow one sample.

Example

About one in four pregnancies meets a complication. Preeclampsia is among the most serious, and today it is mostly recognised once blood pressure has already risen and organs are under strain.

MaiRa looks earlier. It reads molecular signals that maternal blood carries months before symptoms, so obstetric teams can stratify risk at the first-trimester visit instead of waiting for the third.

Prenatal care that anticipates instead of reacting, with MaiRa

Request information for your clinic

Hands resting on a pregnant belly
A partner's hand reaching towards a pregnant belly
Protecting the health of mother and baby by anticipating risk before symptoms appear

Why preeclampsia matters

  • 1 in 20 pregnancies
  • around 76,000 maternal deaths a year
  • around 500,000 fetal deaths a year
  • long-term effects for mother and child
  • detected, too often, too late

The hardest part of preeclampsia is not treatment. It is spotting it in the preclinical phase, when prevention can still change its course.

How clinicians order MaiRa

A simple clinical flow with no extra complex tests. The same blood draw used for NIPT can serve both.

Illustration of a maternal blood sample tube: plasma with cell-free RNA above the blood cells
Weeks 9 to 14

Maternal blood sample

Drawn at the routine first-trimester visit, compatible with NIPT.

In our laboratory

Molecular analysis

Cell-free RNA is extracted from plasma and read with next-generation sequencing.

Report

Individual risk estimate

A predictive AI model turns the signature into a personal risk result for the obstetric team.

What an early result makes possible

Risk stratification
Identify high-risk patients and optimise obstetric follow-up from the first trimester.
Preventive intervention
Start low-dose aspirin before week 16 and adjust clinical management while it can still help.
Personalised monitoring
Blood pressure, organ function, fetal growth and placental function, watched where it matters most.
Expected impact
Fewer early-onset preeclampsia cases, less prematurity and fewer neonatal ICU admissions.
Pregnant woman in evening sunlight

Built on 9,600 pregnancies

MaiRa comes out of PREMOM, a prospective multicentre study that followed women through every trimester and showed what cell-free RNA can do in early preeclampsia screening.

14participating hospitals
~9,600pregnant women enrolled
26,000samples collected
2025results published in Nature Communications
Read about the study

Bring first-trimester prediction to your patients

For hospitals, fertility and prenatal clinics and laboratories. Tell us about your practice and we will share how MaiRa fits your workflow.

Request information